Home » Topics » BioWorld Science

BioWorld Science
RSS

OPT-CHF phase II study of oxypurinol recommended to continue

July 14, 2004

Grant for Alzheimer's diagnostic work at Samaritan and Georgetown University

July 14, 2004

Cytorex Biosciences completes cytotoxicity testing with Cytoreg

July 14, 2004

McNeil and ICAgen enter agreement for ICA-17043 for sickle cell anemia

July 14, 2004

New Glimicron presentation launched in Japan

July 14, 2004

Studies highlight pimecrolimus efficacy in children with atopic dermatitis

July 14, 2004

Good safety and acceptability profile found with Carraguard in HIV-positive patients

July 13, 2004

CRF1 receptor antagonists for anxiety, affective disorders, etc.

July 13, 2004

Inhibitors of receptor tyrosine kinases claimed by Array BioPharma

July 13, 2004

Takeda patent claims compounds that inhibit somatostatin receptor binding

July 13, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
In the clinic for June 12, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...